News on Wellness

Amgen Provides Results on Phase 3 Study of Talimogene Laherparepvec


Amgen has made an announcement of their top line results from the primary overall survival analysis of a Phase 3 trial in melanoma that evaluates the safety and efficiency of talimogene laherparepvec which can be used for the treatment of unresected stage 3B, 3C or 4 melanoma.AMGENAmgen said that the primary end point of OS was not met as it was mentioned earlier, and also the secondary end point was not met, but Amgen did mention that they have seen better trends in favor of talimogene laherparepvec that will help them to improve in the future.

The company also revealed that the estimated OS hazard ratio and the improvement in median OS were identical to the earlier analysis. The drugmaker said that they still are encouraged to go ahead with their study and to meet the primary end point and achieve better results in the future. The company officials mentioned that they have missed the statistical significance of the secondary end point but they still support the fact that talimogene laherparepvec can help in understanding the role of melanoma, both as a single agent and in combination with other therapies.

Amgen also mentioned that the most common and serious adverse events that have occurred include disease progression, fever and bacterial skin infection. The company had earlier mentioned that they have seen improvement in survival rate by 21% for patients with advanced forms of melanoma. The announcement had very little to no effect on the shares in the stock market which indicates strong position of the firm in the market.

Leave a Reply

Your email address will not be published. Required fields are marked *